The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia

Other OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Danazol therapy at 400 mg/day for 3 months effectively regressed endometrial hyperplasia in 95.9% of postmenopausal women, with only two cases showing persistent hyperplasia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Forty eight patients in postmenopause affected by histologically confirmed endometrial hyperplasia (34 with simplex and 14 with complex forms) were administered Danazol therapy, 400 mg/day for 3 consecutive months. At the end of treatment, regression of the endometrial hyperplasia was histologically ascertained in 46 patients (95.9%) with disappearance of the metrorrhagia. Endometrial atrophy was obtained in 75% of the cases, while secretive (14.7%) or proliferative (6.2%) aspects resulted in the others. Only 2 patients (4.1%) showed persistence of the hyperplastic endometrium. On the basis of this experience, treatment with Danazol appears to be effective and safe with only scarce and transient side effects. This therapy is therefore proposed as a valid alternative to progestogen therapy in cases of postmenopausal endometrial hyperplasia.

My notes (saved in your browser only)

MeSH descriptors

Danazol Endometrial Hyperplasia Menopause Aged Danazol Endometrial Hyperplasia Female Humans Middle Aged Prospective Studies Treatment Outcome

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (6)

Source provenance

openalex
last seen: 2026-05-10T11:38:03.782131+00:00
pubmed
last seen: 2026-10-08T21:02:06.159351+00:00
License: CC0 · commercial use OK